Io­vance’s reg­is­tra­tional lung can­cer tri­al on hold af­ter pa­tient death

The FDA placed a clin­i­cal hold on a reg­is­tra­tional tri­al of Io­vance Bio­ther­a­peu­tics’ tu­mor-in­fil­trat­ing lym­pho­cyte, or TIL, ther­a­py LN-145 af­ter a pa­tient death in the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER